23andMe SPAC Presentation Deck

We Have Generated a Deep Pipeline Across Multiple Therapeutic Areas Immuno-oncology P006¹ Cardio Metabolic NASH Dyslipidemia Other Immunology CD96 Neurology, Other Multiple Multiple Multiple Multiple Preclinical Note: As of January 15, 2021.1 Most projects are joint with GSK; P006 is a 23and Me wholly owned program. Phase 1 Phase 2 Phase 3 Next Milestone Phase 1 Data First Time in Human 23and Me Confidential and Proprietary Information 27

View entire presentation